A new study led by researchers at the University of Barcelona in Spain recently revealed the reason behind discrepant outcomes when administering antagonist drugs for brain disorders. The study was published in the journal Proceedings of the National Academy of Sciences (PNAS) and is entitled “…
Parkinson’s disease is still the second most common neurodegenerative disorder affecting millions of people worldwide. A multidisciplinary team of researchers from UCL, the University of Cambridge and the University of Sheffield, have recently published a study in Nature Neuroscience linking a Parkinson’s disease-causing mutation in the Fbx07 gene…
Neurodegenerative diseases correspond to a range of debilitating conditions that primarily result in the degeneration and/or death of brain and spinal cord neurons. Parkinson’s disease is one example of a progressive neurodegenerative disorder that develops gradually, with patients usually experiencing the first symptoms around the age of 60 or older.
Recently, a group of researchers from the Buck Institute for Age Research in Novato, California released study results in which they found that low-dose lithium reduced involuntary motor movements – the troubling side effect of the medication most commonly used to treat Parkinson’s disease (PD). The study, entitled, “…
A multidisciplinary team of researchers from the London School of Hygiene & Tropical Medicine (LSHTM), have recently released results from a retrospective study showing that Glitazone, a type of drug used to treat diabetes may reduce the risk of developing Parkinson’s disease (PD). The study, entitled, “…
New encouraging data on novel therapeutic drugs targeting components affected in several brain diseases linked to dementia have been recently presented at the Alzheimer’s Association International Conference 2015 (AAIC 2015) in Washington, D.C. The brain diseases considered included Parkinson’s disease, Alzheimer’s disease and Lewy Body dementia. All three conditions…
In a recent pilot study published in the journal Digital Health a team of researchers are testing new technologies for Parkinson’s disease (PD) which may influence clinical research in personal genetic testing to better diagnose and potentially treat PD. “These findings demonstrate that remote recruitment and conduct…
Amarantus BioScience Holdings, Inc., a biotechnology company focused on advancing therapeutic and diagnostic products for orphan and neurologic diseases, recently announced they have dosed the first patient in a Phase 2b clinical trial of flagship neurology pipeline drug eltoprazine, indicated as a potential treatment for Parkinson’s disease levodopa-induced dyskinesia (PD-LID).
In a new study entitled “Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson’s disease” an international team of scientists discovered that anti-malaria drugs chloroquine and amodiaquine are potential therapeutics for Parkinson’s disease. The study was published in…
Symptoms associated with Parkinson’s disease include tremor, muscle stiffness, and slowed movement that make it difficult to execute such simple tasks as holding an eating utensil steady, and patients currently have few options for relief outside of a hospital or clinic. Some medications can help, but over time they tend…
Get regular updates to your inbox.